3 Profitable Stocks We’re Skeptical Of

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

OSK Cover Image

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.

Oshkosh (OSK)

Trailing 12-Month GAAP Operating Margin: 7.5%

Oshkosh (NYSE:OSK) manufactures specialty vehicles for the defense, fire, emergency, and commercial industry, operating various brand subsidiaries within each industry.

Why Does OSK Give Us Pause?

  1. Demand cratered as it couldn’t win new orders over the past two years, leading to an average 3.3% decline in its backlog
  2. Gross margin of 16.3% is below its competitors, leaving less money to invest in areas like marketing and R&D
  3. Earnings per share have dipped by 11.9% annually over the past two years, which is concerning because stock prices follow EPS over the long term

Oshkosh’s stock price of $152.86 implies a valuation ratio of 11.7x forward P/E. Dive into our free research report to see why there are better opportunities than OSK.

The Pennant Group (PNTG)

Trailing 12-Month GAAP Operating Margin: 5.7%

Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ:PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors.

Why Does PNTG Fall Short?

  1. Smaller revenue base of $1.09 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
  2. Low free cash flow margin of 2.4% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
  3. 6× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly

The Pennant Group is trading at $39.30 per share, or 26.2x forward P/E. If you’re considering PNTG for your portfolio, see our FREE research report to learn more.

Sysco (SYY)

Trailing 12-Month GAAP Operating Margin: 3.7%

Powering more than 730,000 commercial kitchens across North America and Europe, Sysco (NYSE:SYY) is a global food distributor that supplies restaurants, healthcare facilities, schools, hotels, and other foodservice establishments with food products and related services.

Why Do We Pass on SYY?

  1. Unit sales averaged 0.9% growth over the past two years and imply healthy demand for its products
  2. Free cash flow margin is expected to remain in place over the coming year
  3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $83.00 per share, Sysco trades at 16.5x forward P/E. Read our free research report to see why you should think twice about including SYY in your portfolio.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article